The reserve of stem-like T cells that lets your immune system outlast a cancer is the same reserve that lets an autoimmune disease grind on for decades, and in mice a single gene called LEF1 sits at the switch. Turn it up and you build more of the fighters that keep a tumor or a chronic virus in check. Delete it and you protect the animal against autoimmune diabetes, because the cells attacking its own pancreas can no longer sustain themselves. One lever, opposite clinical directions. That double edge is the uncomfortable core of a paper published in Cell on July 1, and to see why it cuts both ways you have to start with a mistake the field believed for the better part of a decade.

For years the story about checkpoint drugs was that they “revive exhausted T cells,” rousing tired soldiers back to the front. A PD-1 blocker would melt a tumor in one melanoma patient and do nothing measurable in the person in the next chair, and the exhaustion story never really explained the gap. Around 2019 several labs converged on the correction. The T cells that respond to checkpoint blockade are not the exhausted frontline troops at all. They are a rare, quiet reserve, a stem-like progenitor population marked by a transcription factor called TCF1, sitting behind the lines and slowly replenishing the fighters that burn out. A 2019 study in Immunity showed that if you ablate those TCF1-positive cells, the response to immunotherapy collapses. The drug does not resurrect the dying. It expands the reserve. Everything since has been an effort to understand that reserve well enough to engineer it.

The new work, from Svetlana Miakicheva and Katrina Hawley in Andrea Schietinger’s lab at Memorial Sloan Kettering, with Doron Betel’s group at Weill Cornell, pushes on the sister of that famous gene. LEF1 and TCF1 are both Wnt-pathway transcription factors, frequently co-expressed and long suspected of doing overlapping work. Using CRISPR to delete LEF1 in mice, the team watched the stem T cell pool lose its ability to persist and self-renew. Schietinger put the effect about as plainly as a scientist ever does: “Turn it up, and you get more stem cells. Remove it, and the stem cell pool disappears.” This is not a subtle knob. It behaves like a master switch for whether the reserve exists at all.

A gene is not enough. The cells need an address.

Then the result that turns this from a gene story into something harder. LEF1 alone does not make a stem T cell. The cell also has to sit in the right physical place, a specialized microenvironment the researchers describe with the same word hematologists use for bone marrow: a niche. When they disrupted the spatial signals holding cells in that location, by blocking integrins or interfering with the Notch pathway, the stem T cell population collapsed even where the genetic program was intact. Stemness is a property of a cell and its address at once, not a setting you can flip in isolation.

That is where the engineering dream runs into a wall. The field has been chasing the shortcut of immortalizing therapeutic T cells by cranking up a single transcription factor, and there is real appetite for it: earlier work has shown that pushing factors like TCF1 reshapes CAR-T cells toward a stem-like, less exhausted state. But if the niche result holds, the hard part was never turning LEF1 on. It is rebuilding the physical signals that let an engineered cell stay stem-like once you have. You cannot ship a neighborhood in a vector.

The study then did what most single-disease papers never attempt. The researchers ran the same analysis across two conditions that look like opposites: a chronic viral infection, where you want the T cells to keep fighting, and type 1 diabetes, where the T cells are the disease. Boosting LEF1 in the infection model reduced exhaustion, the outcome you would hope for. Deleting it in the autoimmune model protected the mice, because the diabetes-causing T cells could no longer renew. When they compared the molecular fingerprints of the stem T cells from both diseases, the profiles clustered as if they were the same cells, with 117 genes switching on and off in an identical pattern. The reserve that lets your immune system outlast a virus runs the same program as the reserve that lets an autoimmune attack persist for decades. It is a pattern that keeps reappearing wherever an immune response refuses to quit: a 2024 Nature Immunology study found the same TCF1-LEF1 co-expression marking a multipotent progenitor across a range of human allergic diseases.

So the same intervention points in two directions. A therapy that strengthens the LEF1 niche to keep cancer-fighting T cells alive is, read from the autoimmune ward, a therapy that could keep a self-destructive attack alive just as well. The paper does not resolve that tension. It defines it, and it leaves two things unresolved on purpose. This is mouse work, CRISPR edits and viral models, not a human trial, and the niche finding is precisely what complicates the fastest commercial path, because a neighborhood is far harder to patent than an inserted gene. Worth noting who paid for the basic biology underneath it all: the intramural programs of the NCI, NIDDK, and NIAID, the Cancer Research Institute, and MSK, publicly and philanthropically funded science of the kind companies tend to build billion-dollar products on top of long after the public money did the risky part.

What to watch is concrete. The translational question is whether the CAR-T field can build or borrow a niche, giving engineered T cells not just the LEF1 program but a place to keep it running, and whether cells made that way hold their numbers in a human patient rather than a mouse. Schietinger’s group has now handed the engineers both halves of the problem, the switch and the address it has to live at. The next real signal will come from the first CAR-T construct that tries to supply both, and whether its cells are still there months after infusion.

Sources

  1. News-Medical – LEF1 and niche-derived factors regulate T cell stemness across chronic diseases (2026)
  2. Cell – Miakicheva, Hawley et al., “LEF1 and niche factors determine T cell stemness across chronic diseases” (2026)
  3. Immunity – Siddiqui et al., intratumoral Tcf1+PD-1+ stem-like CD8+ T cells drive response to checkpoint blockade (2019)
  4. Science Translational Medicine – transcription-factor control of CAR T cell stemness and exhaustion (2022)
  5. Nature Immunology – TCF1-LEF1 co-expression identifies a multipotent progenitor across human allergic diseases (2024)